Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

Posted by George Bondi on Aug 14th, 2026

Upstream Bio (NASDAQ:UPB – Get Free Report) had its price objective lifted by equities researchers at JPMorgan Chase & Co. from $8.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 29.22% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Mizuho decreased their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Truist Financial dropped their price target on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, HC Wainwright initiated coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective for the company. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Upstream Bio presently has an average rating of “Hold” and a consensus target price of $29.67.

Get Our Latest Analysis on Upstream Bio

Upstream Bio Trading Up 0.8%

Shares of UPB traded up $0.06 during midday trading on Friday, reaching $6.96. 176,117 shares of the company were exchanged, compared to its average volume of 875,161. Upstream Bio has a 1-year low of $5.85 and a 1-year high of $33.68. The stock has a 50-day moving average price of $6.80 and a 200-day moving average price of $9.92. The company has a market cap of $381.47 million, a price-to-earnings ratio of -2.39 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 45.92% and a negative net margin of 4,955.67%. Equities research analysts anticipate that Upstream Bio will post -2.87 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Upstream Bio during the second quarter worth about $25,973,000. Norges Bank bought a new stake in Upstream Bio in the fourth quarter valued at about $78,264,000. Vanguard Group Inc. raised its stake in Upstream Bio by 12.5% during the third quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after buying an additional 271,718 shares in the last quarter. UBS Group AG lifted its holdings in Upstream Bio by 563.4% during the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after buying an additional 1,533,972 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in Upstream Bio during the 4th quarter worth approximately $41,423,000.

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.